Last reviewed · How we verify
cisplatin, mitomycin-C, doxifluridine
This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Gastric cancer (phase 3 trial context).
At a glance
| Generic name | cisplatin, mitomycin-C, doxifluridine |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication. Mitomycin-C is a mitomycin antibiotic that alkylates DNA and generates reactive oxygen species. Doxifluridine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting nucleotide synthesis. Together, these agents provide multi-modal cytotoxic activity against rapidly dividing cancer cells.
Approved indications
- Gastric cancer (phase 3 trial context)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Anemia
Key clinical trials
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cisplatin, mitomycin-C, doxifluridine CI brief — competitive landscape report
- cisplatin, mitomycin-C, doxifluridine updates RSS · CI watch RSS
- Asan Medical Center portfolio CI